[Studies on C1 inactivator resistant fibrinolytic activity]. 1991

A Deguchi, and K Kawamura, and K Deguchi, and S Tamaki, and M Tanigawa, and E Iwasaki, and H Wada, and S Murashima, and M Nishikawa, and S Shirakawa
Oyamada Memorial Spa Hospital, Yokkaichi.

The fibrin lysis activity in the presence of enough quantity of C1 inactivator (C1.INA) is called C1.INA resistant fibrinolytic activity (C1.IRFA). C1.INA inhibits the activation of intrinsic fibrinolysis, therefore C1.IRFA is considered to reflect the extrinsic fibrinolytic activity mainly. We studied the effect of C1.INA using fibrin plate assay on fibrin lysis activity (FLA) and C1.IRFA in normal individuals and pregnant women, and studied the fluctuation of FLA and C1.IRFA during venous occlusion test (VO) or 1-deamino-8-D-arginine vasopressin (DDAVP) administration. After VO or DDAVP administration, the euglobulin lysis time (ELT) was reduced, FLA increased and C1.IRFA also increased. The increase in C1.IRFA accounted for most of the increase in FLA. Therefore, the increased fibrinolytic activity during VO or DDAVP administration is due to extrinsic fibrinolytic activity. In the pregnant women, the fibrinolytic activity was decreased during pregnancy and the low fibrinolytic activity is suggested to be involved in the low extrinsic fibrinolytic activity. The measurement of C1.IRFA is considered to be useful.

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D003174 Complement C1 Inactivator Proteins Serum proteins that inhibit, antagonize, or inactivate COMPLEMENT C1 or its subunits. Complement 1 Esterase Inhibitors,Complement C1 Inactivating Proteins,Complement C1 Inhibiting Proteins,Complement C1 Inhibitor Proteins,Complement C1r Protease Inhibitor Proteins,Complement C1s Esterase Inhibitor Proteins,Complement Component 1 Inactivator Proteins
D003894 Deamino Arginine Vasopressin A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR. Desmopressin,Vasopressin, Deamino Arginine,1-Deamino-8-D-arginine Vasopressin,1-Desamino-8-arginine Vasopressin,Adiuretin,Adiuretin SD,Apo-Desmopressin,DDAVP,Desmogalen,Desmopressin Acetate,Desmopressin Monoacetate,Desmopressin Monoacetate, Trihydrate,Desmopressine Ferring,Desmospray,Desmotabs,Minirin,Minurin,Nocutil,Octim,Octostim,Acetate, Desmopressin,Arginine Vasopressin, Deamino,Ferring, Desmopressine,Monoacetate, Desmopressin,Monoacetate, Trihydrate Desmopressin,Trihydrate Desmopressin Monoacetate,Vasopressin, 1-Deamino-8-D-arginine,Vasopressin, 1-Desamino-8-arginine
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Deguchi, and K Kawamura, and K Deguchi, and S Tamaki, and M Tanigawa, and E Iwasaki, and H Wada, and S Murashima, and M Nishikawa, and S Shirakawa
January 1976, Haemostasis,
A Deguchi, and K Kawamura, and K Deguchi, and S Tamaki, and M Tanigawa, and E Iwasaki, and H Wada, and S Murashima, and M Nishikawa, and S Shirakawa
January 1976, Methods in enzymology,
A Deguchi, and K Kawamura, and K Deguchi, and S Tamaki, and M Tanigawa, and E Iwasaki, and H Wada, and S Murashima, and M Nishikawa, and S Shirakawa
August 1978, Thrombosis research,
A Deguchi, and K Kawamura, and K Deguchi, and S Tamaki, and M Tanigawa, and E Iwasaki, and H Wada, and S Murashima, and M Nishikawa, and S Shirakawa
April 1988, Kokyu to junkan. Respiration & circulation,
A Deguchi, and K Kawamura, and K Deguchi, and S Tamaki, and M Tanigawa, and E Iwasaki, and H Wada, and S Murashima, and M Nishikawa, and S Shirakawa
March 1975, The Journal of clinical investigation,
A Deguchi, and K Kawamura, and K Deguchi, and S Tamaki, and M Tanigawa, and E Iwasaki, and H Wada, and S Murashima, and M Nishikawa, and S Shirakawa
January 1981, Thrombosis research,
A Deguchi, and K Kawamura, and K Deguchi, and S Tamaki, and M Tanigawa, and E Iwasaki, and H Wada, and S Murashima, and M Nishikawa, and S Shirakawa
March 1970, The Journal of clinical investigation,
A Deguchi, and K Kawamura, and K Deguchi, and S Tamaki, and M Tanigawa, and E Iwasaki, and H Wada, and S Murashima, and M Nishikawa, and S Shirakawa
January 1971, Zeitschrift fur medizinische Mikrobiologie und Immunologie,
A Deguchi, and K Kawamura, and K Deguchi, and S Tamaki, and M Tanigawa, and E Iwasaki, and H Wada, and S Murashima, and M Nishikawa, and S Shirakawa
November 1969, Indian journal of medical sciences,
A Deguchi, and K Kawamura, and K Deguchi, and S Tamaki, and M Tanigawa, and E Iwasaki, and H Wada, and S Murashima, and M Nishikawa, and S Shirakawa
January 2017, PloS one,
Copied contents to your clipboard!